Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-intensity allogeneic stem cell transplantation for relapsed or refractory childhood anaplastic large cell lymphoma
jRCTs041190066Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fludarabine and melphalan in anaplastic large cell lymphoma (ALCL), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Post-transplant 1-year event-free survival rate. Started Feb 2020; status: recruiting.
02
Drugs
fludarabinemelphalan
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on jRCTs041190066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190066.